T 1100

Drug Profile

T 1100

Alternative Names: HIV38p; T 09115

Latest Information Update: 07 May 1998

Price : $50

At a glance

  • Originator Antigenics
  • Class Antivirals; Nucleotides
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 07 May 1998 Preclinical development discontinued
  • 07 May 1998 Discontinued-Preclinical for HIV-1 infections in USA (Unknown route)
  • 01 Dec 1994 Preclinical development for HIV-1 infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top